Research programme: DNA gyrase inhibitors - AstraZeneca

Drug Profile

Research programme: DNA gyrase inhibitors - AstraZeneca

Alternative Names: Pyrrolamide-based antibacterials - AstraZeneca

Latest Information Update: 05 Oct 2011

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Amides; Naphthyridines; Pyrroles; Quinolines
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 20 Sep 2011 Preclinical antimicrobial and pharmacodynamics data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011) ,
  • 01 Sep 2011 Preclinical development is ongoing
  • 15 Sep 2009 Preclinical antimicrobial and pharmacodynamics data presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top